OptiNose — Q3 2021 Earnings Presentation
22 slides from OptiNose's earnings presentation, Nov 16, 2021
Slide 1: Building a Leading ENT / Allergy Specialty Company
Building a Leading ENT / Allergy Specialty Company C o r p o r a t e P r e s e n t a t i o n N o v e m b e r 1 6 , 2 0 2 1 Exhibit 99.1
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this
Slide 3: XHANCE Continues to Have Significant Growth Potential
XHANCE® Continues to Have Significant Growth Potential
Slide 4: Opportunity for Substantial Continuing Growth with the Nasal Polyps Indication
4 Opportunity for Substantial Continuing Growth with the Nasal Polyps Indication in the Current Target Audience Our commercial team promotes XHANCE to a universe of largely ENT and Allergy specialists, with direct sales by representatives deployed against 100 territories augmented by targeted non-pe
Slide 5: XHANCE as First FDA-approved Drug Treatment for Chronic Sinusitis Creates New Growth Opportunities
5 Successful Development of XHANCE as the First FDA-approved Drug Treatment for Chronic Sinusitis Creates Multiple New Opportunities for Growth Today: up to approximately 1 Million patients with nasal polyps (NP) are treated by specialty physicians who are the current focus of our sales deployment
Slide 6: Potential Primary Care Partners Could Enable Promotion for up to 30 Million Patients
6 There are Potential Partners with Current “High Audience Crossmatch” Primary Care Deployments that Could Enable Promotion for up to 30 Million Patients For a Partner, there are 6-7 million NP+CS patients currently treated by a Primary Care Physician and 20 million lapsed patients that could be act
Slide 7: Chronic Sinusitis Phase 3b Clinical Trial Data is a Near-Term Event
7 Chronic Sinusitis Phase 3b Clinical Trial Data is a Near-Term Event Recruitment Completed July 2021 Recruitment Completed October 2021 Top-line results expected in Q1 2022 Top-line results expected in Q2 2022
Slide 8: Q3 2021 Performance
optinose’_ SSS Q3 2021 Performance
Slide 9: Key Takeaways and Q3 2021 Highlights
9 Key Takeaways and Q3 2021 Highlights Consistent Commercial Execution Driving Q3 2021 Growth Multiple Factors Support Continued Revenue Growth FY 2021 Revenue Guidance Implies Y/Y Growth of 47% to 55% +41% XHANCE Net Revenue Growth Q3 2021/Q3 2020 $253 XHANCE Net Revenue per TRx in Q3 2021 $84M Cas
Slide 10: XHANCE New and Total Prescriptions
10 XHANCE New and Total Prescriptions XHANCE New Prescriptions increased 22% and Total Prescriptions increased 25% from Q3 2020 to Q3 2021 Estimated based on monthly prescription data from third parties and XHANCE preferred pharmacy network. The Market on this slide is defined as the sum of all intr
Slide 11: XHANCE Market Share & Prescribers by Prescribing Frequency
11 XHANCE Market Share & Prescribers by Prescribing Frequency The Market on this slide is defined as the sum of all intranasal steroid prescriptions written by physicians in the XHANCE target physician audience of approximately 18,000 physicians. Estimated based on monthly prescription data from thi
Slide 12: Q3 2021 Financial Update
optinose’_ SSS Q3 2021 Financial Update
Slide 13: Financial Review – XHANCE Net Revenue
13 $32.8 $51.1 YTD Sep '20 YTD Sep '21 Financial Review – XHANCE Net Revenue XHANCE Net Revenue Increased 41% from Q3 2020 to Q3 2021 and 56% on a Year-to-Date Basis $15.4 $21.8 Q3 '20 Q3 '21 ($M) +41% Net Revenue Net Revenue +56% ($M)
Slide 14: Financial Review – XHANCE Average Net Revenue per Prescription
14 $224 $253 Q3 '20 Q3 '21 Financial Review – XHANCE Average Net Revenue per Prescription XHANCE Average Net Revenue per TRx Increased from $224 to $253 from Q3 2020 to Q3 2021 and from $175 to $211 on a Year-to-Date Basis $175 $211 YTD Sep '20 YTD Sep '21 +21% Average Net Revenue per TRx Average Ne
Slide 15: Full Year 2021 Financial Guidance
15 Full Year 2021 Financial Guidance XHANCE Net Revenue ‒ Expected to be between $71 – $75 million ‒ Previously expected to exceed $80 million XHANCE Average Net Revenue per Prescription ‒ Expected to exceed $210 ‒ Previously expected to exceed $200 Operating Expense (GAAP) ‒ Expected to be be
Slide 16: Revised Debt Terms
16 Revised Debt Terms1 TTM Revenue Covenants ($ 000’s) Q4 2021 $68,000 Q1 2022 $70,000 Q2 2022 $75,000 Q3 2022 $80,000 Q4 2022 $90,000 Q1 2023 $98,750 Q2 2023 $102,500 Q3 2023 $106,250 Q4 2023 $110,000 Q1 2024 $113,750 Q2 2024 $117,500 Revised XHANCE Net Revenue Covenants ‒ On average ~$15.5M less
Slide 17: Chronic Sinusitis Clinical Trials Update
Chronic Sinusitis Clinical Trials Update
Slide 18: XHANCE Chronic Sinusitis Program
18 XHANCE Chronic Sinusitis Program Announced that recruitment for trial -3206 (ReOpen2) completed in October Recruitment for -3205 (ReOpen1) was previously completed In Q3 we conducted a pre-planned, blinded, interim analysis (IA) to assess variance for the symptom and CT-scan co-primary endp
Slide 19: Closing Remarks
optinose’_ SSS Closing Remarks
Slide 20: Key Takeaways and Q3 2021 Highlights
20 Key Takeaways and Q3 2021 Highlights Consistent Commercial Execution Driving Q3 2021 Growth Multiple Factors Support Continued Revenue Growth FY 2021 Revenue Guidance Implies Y/Y Growth of 47% to 55% +41% XHANCE Net Revenue Growth Q3 2021/Q3 2020 $253 XHANCE Net Revenue per TRx in Q3 2021 $84M Ca
Slide 21: Investor Relations – Optinose
21 Investor Relations – NASDAQ: OPTN Optinose Investor Contact Jonathan Neely, VP, Investor Relations and Business Development 267-521-0531 Investors@optinose.com At 30 September 2021: – $84 million in cash – Long-term debt: $130 million – 53.4 million common shares o/s – 10.8 million options, warra
Slide 22: Building a Leading ENT / Allergy Specialty Company
Building a Leading ENT / Allergy Specialty Company C o r p o r a t e P r e s e n t a t i o n N o v e m b e r 1 6 , 2 0 2 1